SYK - Stryker Corporation
Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently bought shares of Amazon.com, Inc. (NASDAQ: AMZN). In a filing disclosed on August 18th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amazon.com stock on July 8th. The trade occurred in the Representative's "KEAN FAMILY PARTNERSHIP" account. Representative Thomas H. Kean, Jr. also recently
SYK's resilient demand, Mako robotics growth and margin gains support its outlook despite cyber and supply disruptions.
Bank of New York Mellon Corp decreased its stake in Stryker Corporation (NYSE: SYK) by 10.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,548,516 shares of the medical technology company's stock after selling 403,885 shares during the
B. Metzler seel. Sohn and Co. AG bought a new position in shares of Stryker Corporation (NYSE: SYK) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 120,896 shares of the medical technology company's stock, valued at approximately $38,063,000. A number of
Advisors Preferred LLC acquired a new stake in shares of Stryker Corporation (NYSE: SYK) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,300 shares of the medical technology company's stock, valued at approximately $1,404,000. A number
AlpenGlobal Capital LLC bought a new stake in Stryker Corporation (NYSE: SYK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 6,155 shares of the medical technology company's stock, valued at approximately $1,938,000. Stryker makes up about 1.2% of AlpenGlobal Capital LLC's
Advisors Capital Management LLC bought a new position in shares of Stryker Corporation (NYSE: SYK) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 89,485 shares of the medical technology company's stock, valued at approximately $28,173,000. Several other institutional investors
Shares of Stryker Corporation (NYSE: SYK - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-four research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy
Stryker (SYK) rebounded in Q2 with 9% organic growth, restoring confidence after a weak Q1. Both MedSurg & Neurotech and Orthopaedics segments sharply accelerated, indicating Q1 weakness was temporary. Guidance was modestly adjusted, but demand remains strong and growth is broad-based across product lines.
BlackRock Inc. cut its position in Stryker Corporation (NYSE: SYK) by 0.7% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,414,742 shares of the medical technology company's stock after selling 187,307 shares during the quarter. BlackRock Inc. owned about
Argent Trust Co grew its stake in Stryker Corporation (NYSE: SYK) by 66.4% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,889 shares of the medical technology company's stock after purchasing an additional 6,339 shares during the quarter. Argent
AMG National Trust Bank lessened its stake in Stryker Corporation (NYSE: SYK) by 17.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,165 shares of the medical technology company's stock after selling 3,257 shares during the period. AMG National Trust Bank's holdings
Stryker has gained 3.8% since March-end as Mako robotics, hospital capital demand and international growth drive momentum.
Stryker's stronger growth, margin gains and product pipeline support the case, but cyber costs, supply constraints and acquisition execution keep risks elevated.
Stryker enters the second half with Q2 momentum restored, but meeting guidance hinges on production, backlog conversion and managing cyber and supply risks.
Stryker's 13.6% three-month rally reflects stronger sales, margins and production, but execution risks and a premium peer valuation could test further gains.
Wall Street analysts made bold moves Thursday, slashing targets on some names while dramatically upgrading others, and the gap between winners and losers tells a story about where smart money is quietly repositioning ahead of the next market move.
Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.
Stryker NYSE: SYK reported 9% organic sales growth in the second quarter of 2026 and adjusted earnings per share growth of 17.9%, as the medical technology company continued recovering from a cybersecurity incident that disrupted operations earlier in the year.